Gushengtang

Gushengtang

Gushengtang was founded in 2019 by Tu Zhiliang, who serves as Chairman and CEO. His control is structured through Action Thrive Group Limited and Gushitang Ltd alongside a family trust, the TZL Family Trust, consolidating ownership around the founder's vision for an integrated TCM platform. The firm operates a growing network of clinics and hospitals while also pursuing drug development and standardized physician education, making it an unusual hybrid of healthcare operator and vertically integrated corporate investor. Gushengtang's model covers the full TCM value chain — outpatient care, inpatient services, proprietary herbal drug R&D, and talent development through formalized training programs. Its clinical network spans China's top-tier cities (Guangzhou, Beijing, Shanghai, Shenzhen) and Singapore, representing a deliberate concentration in high-density, high-income urban centers. The firm's investor base shapes its strategy: Boyu Capital committed $110 million via a convertible bond subscription in 2026 (per firm disclosures, 2026), supporting domestic clinic expansion, while August Global Partners backs Southeast Asian entry. Early backers include Starr International and Eight Roads, linking Gushengtang to long-duration insurance and growth-equity capital. Gushengtang operates clinics and hospitals in at least five major cities, with its headquarters on Qingsha Road in Guangzhou's Nansha District. While precise team size is undisclosed, the network footprint implies substantial clinical and administrative staffing. In 2026, the Boyu Capital convertible bond became the most significant known operational milestone, marking a transition from early-stage backing to growth-focused institutional capital. Structurally, Gushengtang operates as a corporate entity rather than a traditional Single Family Office, using its balance sheet and strategic investor relationships to fund expansion. The combination of a founder control trust, a network of operating healthcare assets, and institutional co-investors gives it a posture distinct from both pure investment holding companies and physician-led clinical groups. Governance rests with Tu Zhiliang through founder shares and trust structures, with no publicly disclosed path to external professional management succession.